Moderna executives called on investors to wait for more data amid a sharp selloff in its shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.
Suscribirse a:
Enviar comentarios (Atom)
Comentarios
Publicar un comentario
Leave a comment. Thanks!
Comentarios de Facebook